U.S. markets close in 5 hours 21 minutes
  • S&P 500

    4,271.70
    -8.45 (-0.20%)
     
  • Dow 30

    33,741.20
    -19.85 (-0.06%)
     
  • Nasdaq

    13,032.04
    -15.15 (-0.12%)
     
  • Russell 2000

    1,998.77
    -17.84 (-0.88%)
     
  • Crude Oil

    87.94
    -4.15 (-4.51%)
     
  • Gold

    1,791.70
    -23.80 (-1.31%)
     
  • Silver

    20.08
    -0.62 (-2.99%)
     
  • EUR/USD

    1.0194
    -0.0064 (-0.62%)
     
  • 10-Yr Bond

    2.7770
    -0.0720 (-2.53%)
     
  • GBP/USD

    1.2085
    -0.0054 (-0.45%)
     
  • USD/JPY

    133.0350
    -0.4450 (-0.33%)
     
  • BTC-USD

    24,157.99
    -352.09 (-1.44%)
     
  • CMC Crypto 200

    574.38
    -16.38 (-2.77%)
     
  • FTSE 100

    7,491.61
    -9.28 (-0.12%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Revolution Medicines, Inc.
Revolution Medicines, Inc.

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on Tuesday, August 9, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a conference call and webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Conference Call and Webcast Information:

A replay of the webcast will be available on the company’s website shortly after the conference call concludes at https://ir.revmed.com/events-and-presentations and will be archived there for at least 14 days.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are in clinical development. Additional RAS(ON) Inhibitors in development include RMC-9805 (KRASG12D) and RMC-8839 (KRASG13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

Contact Information

David S. Arrington
SVP Investor Relations & Corporate Affairs
Revolution Medicines
650-452-6046
darrington@revmed.com